Acquired by Alcon in Nov 2022
AERI - Aerie Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Durham,
United States
Type: Equity
AERI price evolution
AERI
| (in millions $) | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $54.09 | $39.44 | $56.44 | $37.19 |
| Short term investments | $118.37 | $144.93 | $138.81 | $102.61 |
| Net receivables | $73.88 | $68.08 | $63.62 | $158.83 |
| Inventory | $46.76 | $47.01 | $40.19 | $40.41 |
| Total current assets | $302.81 | $311.41 | $316.97 | $355.65 |
| Long term investments | $3.98 | |||
| Property, plant & equipment | $71.06 | $72.39 | $73.14 | $74.14 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $72.78 | $73.93 | $78.58 | $75.74 |
| Total investments | $118.37 | $144.93 | $142.79 | $102.61 |
| Total assets | $375.59 | $385.34 | $395.55 | $431.39 |
| Current liabilities | ||||
| Accounts payable | $9.06 | $9.28 | $7.88 | $8.29 |
| Deferred revenue | $70.88 | $70.44 | $70 | $64.31 |
| Short long term debt | $4.87 | $4.74 | $4.46 | $4.37 |
| Total current liabilities | $133.33 | $119.66 | $115.29 | $124.99 |
| Long term debt | $332.11 | $332.55 | $332.71 | $256.28 |
| Total noncurrent liabilities | $406.24 | $406.81 | $405.97 | $323.73 |
| Total debt | $336.99 | $337.29 | $337.18 | $260.64 |
| Total liabilities | $539.57 | $526.47 | $521.26 | $448.72 |
| Shareholders' equity | ||||
| Retained earnings | -$1188.04 | -$1161.21 | -$1141.84 | -$1153.91 |
| Other shareholder equity | -$0.8 | -$0.79 | -$0.43 | -$0.13 |
| Total shareholder equity | -$163.98 | -$141.13 | -$125.71 | -$17.33 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $37.19 | $151.57 | $143.94 | $202.82 |
| Short term investments | $102.61 | $88.79 | $165.25 | |
| Net receivables | $158.83 | $56.02 | $38.35 | $2.71 |
| Inventory | $40.41 | $27.06 | $21.05 | $10.11 |
| Total current assets | $355.65 | $331.75 | $376.34 | $220.18 |
| Long term investments | ||||
| Property, plant & equipment | $74.14 | $68.34 | $74.67 | $60.52 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $75.74 | $70.29 | $76.27 | $64.87 |
| Total investments | $102.61 | $88.79 | $165.25 | |
| Total assets | $431.39 | $402.05 | $452.61 | $285.04 |
| Current liabilities | ||||
| Accounts payable | $8.29 | $8.83 | $12.77 | $12.4 |
| Deferred revenue | $64.31 | $50.86 | ||
| Short long term debt | $4.37 | $4.92 | $5.5 | |
| Total current liabilities | $124.99 | $104.47 | $83.65 | $50.78 |
| Long term debt | $256.28 | $220.58 | $200.75 | |
| Total noncurrent liabilities | $323.73 | $273.61 | $202.01 | $6.45 |
| Total debt | $260.64 | $225.5 | $206.25 | |
| Total liabilities | $448.72 | $378.08 | $285.66 | $57.24 |
| Shareholders' equity | ||||
| Retained earnings | -$1153.91 | -$1079.1 | -$896 | -$696.42 |
| Other shareholder equity | -$0.13 | -$0.05 | -$0.09 | |
| Total shareholder equity | -$17.33 | $23.97 | $166.95 | $227.81 |
| (in millions $) | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $36.13 | $33.31 | $29.84 | $114.67 |
| Cost of revenue | $6.93 | $3.74 | $6.78 | $6.07 |
| Gross Profit | $29.2 | $29.57 | $23.05 | $108.6 |
| Operating activities | ||||
| Research & development | $21.99 | $19.56 | $25.17 | $20.85 |
| Selling, general & administrative | $33.88 | $28.15 | $31.52 | $36.01 |
| Total operating expenses | $55.87 | $47.71 | $56.7 | $56.86 |
| Operating income | -$26.67 | -$18.14 | -$33.64 | $51.74 |
| Income from continuing operations | ||||
| EBIT | -$26.73 | -$19.32 | -$35.2 | $46.02 |
| Income tax expense | $0.1 | $0.05 | $0.69 | $0.49 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$26.83 | -$19.37 | -$35.89 | $45.53 |
| Income (for common shares) | -$26.83 | -$19.37 | -$35.89 | $45.53 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $194.13 | $83.14 | $69.89 | $24.18 |
| Cost of revenue | $26.85 | $25.33 | $4.83 | $0.64 |
| Gross Profit | $167.29 | $57.8 | $65.06 | $23.54 |
| Operating activities | ||||
| Research & development | $75.84 | $74.01 | $91.38 | $86.12 |
| Selling, general & administrative | $137.81 | $137.18 | $138.4 | $120.61 |
| Total operating expenses | $213.64 | $213.5 | $252.55 | $233.28 |
| Operating income | -$46.35 | -$155.69 | -$187.49 | -$209.74 |
| Income from continuing operations | ||||
| EBIT | -$74.22 | -$177.86 | -$199.67 | -$232.57 |
| Income tax expense | $0.59 | $5.25 | -$0.09 | $0 |
| Interest expense | ||||
| Net income | ||||
| Net income | -$74.81 | -$183.1 | -$199.58 | -$232.57 |
| Income (for common shares) | -$74.81 | -$183.1 | -$199.58 | -$232.57 |
| (in millions $) | 30 Sep 2022 | 30 Jun 2022 | 31 Mar 2022 | 31 Dec 2021 |
|---|---|---|---|---|
| Net income | -$26.83 | -$19.37 | -$35.89 | $45.53 |
| Operating activities | ||||
| Depreciation | $3.35 | $3.42 | $3.61 | $9.78 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $3.64 | $3.96 | $4.63 | $6.17 |
| Total cash flows from operations | -$11.4 | -$13.23 | $61.91 | -$30.11 |
| Investing activities | ||||
| Capital expenditures | -$0.81 | -$1.37 | -$1.6 | -$0.75 |
| Investments | $26.68 | -$2.56 | -$40.7 | $2.81 |
| Total cash flows from investing | $25.86 | -$3.93 | -$42.3 | $2.06 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.19 | $0.17 | -$0.36 | $3.39 |
| Net borrowings | ||||
| Total cash flows from financing | $0.19 | $0.17 | -$0.36 | $3.39 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $14.65 | -$17 | $19.25 | -$24.66 |
| (in millions $) | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 | 31 Dec 2018 |
|---|---|---|---|---|
| Net income | -$74.81 | -$183.1 | -$199.58 | -$232.57 |
| Operating activities | ||||
| Depreciation | $37.5 | $34.16 | $18.11 | $2.44 |
| Business acquisitions & disposals | -$7.83 | |||
| Stock-based compensation | $29.52 | $40.09 | $45.09 | $38.73 |
| Total cash flows from operations | -$99.15 | -$64.69 | -$150.43 | -$152.58 |
| Investing activities | ||||
| Capital expenditures | -$3.29 | -$3.1 | -$9.96 | -$31.31 |
| Investments | -$14.91 | $76.28 | -$165.45 | $52.1 |
| Total cash flows from investing | -$18.2 | $73.18 | -$183.25 | $20.79 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $2.97 | $0.76 | $135.97 | |
| Net borrowings | $308.35 | -$1.88 | ||
| Total cash flows from financing | $2.97 | -$0.86 | $274.8 | $137.04 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$114.38 | $7.63 | -$58.88 | $5.25 |
News
|
ImmunoGen (IMGN) Q3 Loss Wider, Sales Beat, '22 View Up
Zacks via Yahoo Finance
7 Nov 2022
|
|
Aerie Pharmaceuticals (AERI) Reports Q3 Loss, Tops Revenue Estimates
Zacks via Yahoo Finance
3 Nov 2022
|
|
Zoetis' (ZTS) Lags Q3 Earnings Estimates, Lowers 2022 Guidance
Zacks via Yahoo Finance
3 Nov 2022
|
|
The Zacks Analyst Blog Highlights SilverBow Resources, Amalgamated Financial, PHX Minerals,...
Zacks via Yahoo Finance
24 Oct 2022
|
|
Corcept (CORT) Thrives on Korlym, Overdependence a Concern
MSN News
23 Oct 2022
|
|
Talaris (TALS) Down on Patient Death From Renal Transplant Study
Zacks via Yahoo Finance
21 Oct 2022
|
|
5 Small Hidden Gems Flying High Despite Market's Bloodbath
Zacks via Yahoo Finance
21 Oct 2022
|
|
Add These 4 Top-Ranked Liquid Stocks For Healthy Gains
Zacks via Yahoo Finance
21 Oct 2022
|
|
RedHill Biopharma (RDHL) Up on New Patent for COVID-19 Candidate
Zacks via Yahoo Finance
20 Oct 2022
|
|
5 Stocks to Bet on in an Innovation-Driven Drug Industry
Zacks via Yahoo Finance
20 Oct 2022
|
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 49.39M |
| Revenue | $213.94M |
|---|---|
| EBITDA | -$15.07M |
| EBIT | -$35.23M |
| Net Income | -$36.55M |
| Revenue Q/Q | 23.25% |
| Revenue Y/Y | 105.41% |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | -3.30 |
| Cash/Share | 1.10 |
| EPS | -$0.74 |
|---|---|
| ROA | -9.21% |
| ROE | 32.63% |
| Debt/Equity | -25.89 |
|---|---|
| Net debt/EBITDA | -32.22 |
| Current ratio | 2.27 |
| Quick ratio | 1.92 |